Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
most of the negatives have been addressed such as penalty by the Las Vegas Authority and also winning the court case with its Bahmas partner and successfully obtained the NY license. instead of rebound, it cont to dive down until 2.20 price which is around the margin call price.
yet to revert formally to UK MHRA even after almost 7 months. there could be complications in the data gathering and have exceeded the 6 months time frame.
the boss is buying warrants and converting. why is he converting higher cost of warrants than buying the shares directly from the market? not making biz sense here.
the main game changer would be the settlement with Uni Melaka..don't forget that s the root cause for causing PN17 back in 2023. as for other hanky panky transaction with previous directors, that wont be able to recoup but mark as impairment for the past two years.
